首页> 外文OA文献 >Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies
【2h】

Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies

机译:用于定量体外药代动力学研究的整合肠和肝微生物系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Investigation of the pharmacokinetics (PK) of a compound is of significant importance during the early stages of drug development, and therefore several in vitro systems are routinely employed for this purpose. However, the need for more physiologically realistic in vitro models has recently fueled the emerging field of tissue-engineered 3D cultures, also referred to as organs-on-chips, or microphysiological systems (MPSs). We have developed a novel fluidic platform that interconnects multiple MPSs, allowing PK studies in multi-organ in vitro systems along with the collection of high-content quantitative data. This platform was employed here to integrate a gut and a liver MPS together in continuous communication, and investigate simultaneously different PK processes taking place after oral drug administration in humans (e.g., intestinal permeability, hepatic metabolism). Measurement of tissue-specific phenotypic metrics indicated that gut and liver MPSs can be fluidically coupled with circulating common medium without compromising their functionality. The PK of diclofenac and hydrocortisone was investigated under different experimental perturbations, and results illustrate the robustness of this integrated system for quantitative PK studies. Mechanistic model-based analysis of the obtained data allowed the derivation of the intrinsic parameters (e.g., permeability, metabolic clearance) associated with the PK processes taking place in each MPS. Although these processes were not substantially affected by the gut-liver interaction, our results indicate that inter-MPS communication can have a modulating effect (hepatic metabolism upregulation). We envision that our integrative approach, which combines multi-cellular tissue models, multi-MPS platforms, and quantitative mechanistic modeling, will have broad applicability in pre-clinical drug development.
机译:在药物开发的早期阶段,对化合物的药代动力学(PK)的研究非常重要,因此,通常会为此目的采用几种体外系统。但是,最近对生理上更现实的体外模型的需求推动了组织工程3D培养物(也称为芯片上器官或微生理系统(MPS))的新兴领域。我们已经开发了一种新颖的流体平台,可以将多个MPS互连起来,从而可以在多器官体外系统中进行PK研究,并可以收集大量的定量数据。在此使用该平台将肠道和肝脏MPS连续整合在一起,并同时研究在人类口服药物后发生的不同PK过程(例如,肠道通透性,肝代谢)。组织特异性表型指标的测量表明,肠道和肝脏MPS可以与循环的普通培养基流体偶联,而不会损害其功能。在不同的实验扰动下研究了双氯芬酸和氢化可的松的PK,结果说明了该集成系统用于定量PK研究的稳定性。对获得的数据进行基于机理模型的分析,可以推导与每个MPS中发生的PK过程相关的内在参数(例如,渗透性,代谢清除率)。尽管这些过程基本上不受肠-肝相互作用的影响,但我们的结果表明,MPS间的通讯可以具有调节作用(肝代谢上调)。我们设想,将多细胞组织模型,多MPS平台和定量机制建模相结合的整合方法将在临床前药物开发中具有广泛的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号